Navigation Links
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
Date:6/26/2010

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA® (exenatide) injection was not increased compared to initiators of other antidiabetic therapies. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

The retrospective study used data accrued over three years from a large, geographically diverse U.S. healthcare insurance claims database to examine the risk of acute pancreatitis in more than 25,000 patients who were treated with BYETTA, relative to nearly 235,000 patients who were treated with other antidiabetes medications. Medical records from claims-identified cases of acute pancreatitis were reviewed by four gastroenterologists, blinded to drug exposure, using a standard assessment tool. In a nested case-control study (NCCS) based on the review, use of BYETTA was not associated with an increased rate of acute pancreatitis compared to the other antidiabetes medications, based on the adjusted odds ratio and 95 percent confidence interval (CI) for current (0.2; CI 0.0-1.4), recent (0.1; CI 0.0-1.3) and past (1.1; CI 0.1-12.3) use of BYETTA.

"This medical records review is consistent with a related earlier analysis of claims data, which showed no evidence for a higher risk of acute pancreatitis associated with the use of BYETTA compared to other common
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Depth charge: Using atomic force microscopy to study subsurface structures
2. Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study
3. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
4. Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis
5. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
6. DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
7. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
8. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
9. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
10. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
11. Reaction Progress Kinetic Analysis to Study Organic Reactions: Free On-Demand Online Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... down the product choices to a manageable shortlist of bench and floor scales ... models that fit best with the customer’s industry and application. , Side-by-side ...
(Date:8/26/2015)... Manhattan, KS (PRWEB) , ... August 26, 2015 ... ... & Biologic Solutions, announces today that a second US laboratory is to open ... in accordance with the continued partnership and long-term growth of research and development ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... its investment in the development and manufacture of highly valued cardiac markers used ... scientific team's extensive expertise with protein chemistry has led to the development and ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation (NYSE: ... today the closing of its previously announced public offering ... the underwriters of their option to purchase an additional ... price of $41.00 per share.  The exercise of the ... common stock sold by Intrexon to 5,609,756 shares and ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... PRINCETON, N.J., March 3 BioWa, Inc. ... agreement with Genentech, Inc. providing,Genentech additional access ... development of select antibodies for potential therapeutic,applications ... "BioWa is pleased to extend this ...
... 29 For the first time,researchers at North ... whose halves are physically or chemically,different -- so-called ... an alternating electrical field is applied to liquid,surrounding ... published in the Feb. 8, 2008, edition,of Physical ...
... - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... on,endocrine therapy and oncology, today announced the ... Vice President, Administrative & Legal,Affairs and Corporate ... of,Vice President and Chief Financial Officer of ...
Cached Biology Technology:BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology 2'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... 2008, Cambridge, UK Any way you slice it, ... , The planarian, a flatworm normally living in ... a single planarian cut into 200 pieces can generate ... is not merely a fascinating master of regeneration, but can ...
... Hosted by Weill Cornell Medical College, the Ansary Symposium ... of leading figures in the field, including internationally known ... and ethical issues in stem cell research. ... -, Thursday, September 18, 8:00 AM-1:30 PM ...
... release is available in French . , Researchers ... of the Jewish General Hospital along with colleagues at ... (OHRI) report a significant breakthrough in the use of viruses ... oncolytic virotherapy. Their results were published in the September early ...
Cached Biology News:Ansary Symposium on Stem Cell Research at Weill Cornell Medical College 2Viral 'magic bullet' targets cancer cells with help of new compound 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The genus Salmonella is a member of ... Gram-negative bacilli that are facultative and flagellated (motile). ... flagellar antigen (phase 1 & 2), the "O" ... and the "Vi" or capsular antigen (referred to ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
Biology Products: